Company Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global healthcare industry group established in 1994, focusing on pharmaceuticals, medical devices, diagnostics, and healthcare services [1] - The company operates in major markets including the US, Europe, Africa, India, and Southeast Asia, with a strong emphasis on innovative drug development in oncology and immunology [1] Innovation and Product Development - Fosun Pharmaceutical employs an open innovation model through self-research, collaboration, licensing, and industrial investment, leading to the launch of innovative products in hematological malignancies, breast cancer, and lung cancer [2] - The company has introduced China's first biosimilar drug Hanlikang®, the first domestic trastuzumab biosimilar Hanquyou®, and the world's first approved anti-PD-1 monoclonal antibody for first-line treatment of small cell lung cancer, Hanshuang® [2] - As of July 2025, Fosun has five rare disease drugs on the market and ten additional indications under research, with its innovative drug Fumainin® approved for dual indications in May 2025 [2] Market Localization and Accessibility - Fosun Pharmaceutical aims to localize international technologies and products in China, enhancing the accessibility of quality medical resources [3] - The company's subsidiary, Fosun Kite, launched the first CAR-T cell therapy product Yikaida®, which is the first CAR-T therapy approved in China, benefiting over 800 lymphoma patients by the end of 2024 [3] - The first domestically produced Da Vinci surgical system was launched in October 2023, making China the only global production base outside the US, with over 670,000 patients treated by the Da Vinci surgical robot by the end of 2024 [3] Global Health Initiatives - Fosun Pharmaceutical is committed to improving the accessibility of medicines in developing countries, particularly in combating malaria in sub-Saharan Africa, where malaria claims a life every minute [4] - The company has developed artesunate for injection, a first-line treatment for severe malaria recommended by WHO, saving over 80 million patients by the end of 2024 [4] - The completion of the first phase of the Côte d'Ivoire park in May 2025 enhances the affordability and accessibility of pharmaceutical products in the region [4]

传闻已久的资生堂医美品牌终于"揭开面纱"！ 2 0 2 5 年 4 月 2 2 日 ， 资 生 堂 中 国 官 宣 旗 下 全 新 医 美 专 研 品 牌 「 律 曜 RQ PYOLOGY 」 （ 以 下 简 称：「律曜」）于上海首发。这是资生堂集团1 5 3年发展史上首个"专为亚洲肌打造"的高端术 研科技美肤品牌，最大的亮点是 以"械妆连用"的产品组合提供医美全周期的护理方案 ，集结 众多独家科技以实现"全面之美"。 对于新品牌的上市，资生堂中国及旅游零售CEO梅津利信表示：" 作为百年东方美先行者，资 生堂中国坚持'双管齐下'的创新战略，引入集团创新的同时，不断加码本土科研投资，把握新 兴的市场机遇。此次发布的律曜品牌将聚焦高端专业医美机构，通过高功效的械妆产品以及优 质的服务体验，为亚洲肌肤提供更安全、高效、精准的全周期美肤解决方案。 " 表面看，「律曜」的上市，意味着资生堂医美战略在中国迎来里程碑式的进展，这家百年老店 有望抓住大热的医美场景机遇迎来一波业务增长。但《FBe a u t y未来迹》研究发现，这一品牌 不仅在研发底层逻辑上有着超前的洞察和系统的解法，更是资生堂集团"成为个人美肤健康公 司 ...